Protalix BioTherapeutics (PLX) Change in Accured Expenses (2010 - 2026)

Protalix BioTherapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $820000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 163.86% year-over-year to $820000.0; the TTM figure through Mar 2026 stood at $2.4 million (up 190.07% YoY), while the FY2025 annual figure was $292000.0, down 58.05% from the prior year.
• Change in Accured Expenses was $820000.0 for Q1 2026 at Protalix BioTherapeutics, down from $4.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.3 million in Q4 2025 to a low of -$3.9 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged $135235.3 across 5 years, with a median of $177000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 503.01% in 2023, then plunged 590.96% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$366000.0 in 2022, then soared by 503.01% to $1.5 million in 2023, then fell by 7.39% to $1.4 million in 2024, then surged by 216.62% to $4.3 million in 2025, then plunged by 81.04% to $820000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $820000.0 (Q1 2026), $4.3 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.